Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil
Polimorfismo dos genes CYO2C9 e VKORC1 em pacientes do Sistema Público de Saúde em um município do Sul do Brasil
Christiane Colet; Mariana Rodrigues Botton; Karin Hepp Schwambach; Tânia Alves Amador; Isabela Heineck
Abstract
Keywords
Resumo
Resumo:
Palavras-chave
References
1 Tavares LC, Marcatto LR, Santos PCJL. Genotype-guided warfarin therapy: current status. Pharmacogenomics. 2018;19(7):667-85.
2 Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. Warfarin pharmacogenomics in diverse populations. Pharmacotherapy. 2017;37(9):1150-63.
3 Sehgal T, Hira JK, Ahluwalia J, et al. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol. Drug Discov Ther. 2015;9(6):404-10.
4 Botton MR, Bandinelli E, Rohde LEP, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol. 2011;72(3):442-50.
5 Colet CF, Amador TA, Heineck I. Drug interactions and adverse events in a cohort of warfarin users attending public health clinics. Int J Cardiovasc Sci. 2018;32(2):110-7.
6 Colet CF, Amador TA, Heineck I. Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil. Braz J Pharm Sci. 2018;54(3):e17738.
7 Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15(3):213-6.
8 Al-Eitan LN, Almasri AY, Khasawneh RH. Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Saudi Pharm J. 2019;27(4):484-90.
9 Perini JA, Struchiner CJ, Silva-Assuncao E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther. 2008;84(6):722-8.
10 Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy antithrombotic therapy and prevention of thrombosis. Chest. 2012;141(2, Suppl):e152S-e184S.
11 Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol. 2013;75(2):334-46.
12 Mandic D, Bozina N, Mandic S, Samardzija M, Milostic-Srb A, Rumora L. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. Int J Clin Pharmacol Ther. 2015;53(11):905-13.
13 Wypasek E, Cieśla M, Suder B, Janik Ł, Sadowski J, Undas A. CYP2C9 polymorphism and unstable anticoagulation with warfarin in patients within the first 3 months following heart valve replacement. Adv Clin Exp Med. 2015;24(4):607-14.
14 Perreault S, Shahabi P, Côté R, et al. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clin Cardiol. 2018;41(5):576-85.
15 Benavides F, Grossman N, Poggi H, et al. Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en indivíduos chilenos. Rev Med Chil. 2015;143(11):1369-76.
16 Biswas M, Bendkhale SR, Deshpande SP, et al. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit. Indian Heart J. 2018;70(Suppl 3):S13-9.
Submitted date:
12/01/2020
Accepted date:
01/31/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email